General Info
Henri Termeer has a track record of guiding the early careers of many industry leaders in the biotech sector. He is known for his constant vision of working together with smart people to solve healthcare problems. Henri Termeer’s investments typically focus on early-stage ventures in the biotechnology industry. He has made 11 investments, with notable exits such as Amylyx Pharmaceuticals. The check size of his investments is not specified. Henri Termeer’s partnership and collaboration styles are not detailed in the available information.
Location: Tilburg, Noord-Brabant, The Netherlands
Country: Netherlands
Industries:
Investment Regions:
Investment Stages: pre-seed, seed
angel-individual
Want to start building warm intros with this investor?
🤖 AI Activity Report
Status: not-found
AI Reasoning: Search results show Henri Termeer was a prominent biotech CEO who died in 2017. The most recent investment linked to him in sources (Amylyx Series A) dates to August 2016. No investments after 2016 were found. Amylyx was the startup he invested in. Time since last known investment is over nine years, which exceeds 12 months. Therefore classify as not-found.
Angel activity thresholds:
Low Activity – Only known angel investments more than 12 months ago.
Active – Known angel investments between the last 12 and 6 months.
Very Active – Known angel investments in the last 6 months.
Investor Contact
Team Members
Name
Role
Email
LinkedIn
…
…
…
…
…
Investment Regions Map
loading map…
Similar Investors
Other similar investors:
Latest on X (Twitter)
Access all contact details of Henri Termeer
Gain instant access to partner names, verified emails, LinkedIn profiles, and more—all in one place. Dive into their portfolio founders and their LinkedIn information, so you can quickly start your outreach and look for warm intros.
Add custom tags to your investor cards. Label them by investment stage, industry focus, interest level, or any other criteria you want to stay organized.
Trusted by Founders like You
Find your matching investors using AI